Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shilpi Arora

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
The Journal of Clinical Endocrinology and Metabolism|September 3, 2010
Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic targetLaura A Marlow, Jaclyn D'Innocenzi, Yilin Zhang, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Journal of Medicinal Chemistry|April 12, 2021
Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library ScreeningJeremy S Disch, Jennifer M Duffy, Esther C Y Lee, et al.
Nature Chemical Biology|May 24, 2016
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cellsMaia Vinogradova, Victor S Gehling, Amy Gustafson, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Cancer Research|June 4, 2024
Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant CancersPatricia J Keller, Elizabeth J Adams, Rentian Wu, et al.
The Journal of Clinical Endocrinology and Metabolism|September 3, 2010
Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic targetLaura A Marlow, Jaclyn D'Innocenzi, Yilin Zhang, et al.
Chemistry & Biology|December 3, 2014
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylationWilliam D Bradley, Shilpi Arora, Jennifer Busby, et al.
Journal of Medicinal Chemistry|April 12, 2021
Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library ScreeningJeremy S Disch, Jennifer M Duffy, Esther C Y Lee, et al.
Nature Chemical Biology|May 24, 2016
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cellsMaia Vinogradova, Victor S Gehling, Amy Gustafson, et al.
Pageof 4